(844) 274-8497



Cancer Pathways 2019: What's New in Oncology


Thank you for your interest in the Dignity Health Cancer Institute of Greater Sacramento's Pathways in Cancer CME Symposium.

Advances in risk assessment, prevention, and screening as well as new drug 
development has led to reduced rates of incidence and mortality for many cancers. As a result of cutting-edge scientific advances such as liquid biopsies and next-generation sequencing cancer patients' face better treatment options than ever before. Keeping up to date with progress in Oncology is challenging but essential. 
  
2019 Event Details
 
Please register below. 

 

February 9, 2019

8:00 a.m. to 1:30 p.m.

Hyatt Regency Sacramento
1209 L. Street 
Sacramento, CA 95814  

7:30 a.m. Registration, breakfast, and networking
8:00 a.m. Welcome
1:30 p.m. Closing Remarks/Adjourn


Our featured presentations will include:

Lung Cancer Screening

Raja Flores, MD

Best Practices in Cardio-Oncology
Amardeep Singh, MD

Intro to Genomics
Damon Hostin

Utilizing Clinical Genomic Testing for Advancing Patient Care
Brian Y. Merritt, MD

Hereditary Cancer Testing: The Past, The Present, and The Future 
Ashley Navarro, MS, CGC

Integrative Oncology
Sonia Reichert, MD


At the conclusion of this program participants should be able to implement the following changes in their professional practice:

  • Identify patients eligible for screening and go over nuances of screening.
  • Recognize which oncology patients are at a higher risk of cardiac disease and toxicity from cancer therapies, monitor, and modify medical therapy for cardio protection.
  • Recognize when to order genomic testing, how to interpret the results, and use test results to direct patient care.
  • Identify patients at risk for hereditary cancer and utilize genetic test results in medical management.
  • Review the benefits of an integrative approach to cancer or patients throughout the continuum of care.

Disclosures:

As a provider accredited by the Institute for Medical Quality/California Medical Association, we must ensure balance, independence, objectivity and scientific rigor in all of our sponsored educational activities. We at Dignity Health Sacramento Office of Continuing Medical Education adhere to the ACCME Standards for Commercial Support.

  • Dr. DiPerna, Dr. Flores, Dr. Singh, Dr. Merritt, Dr. Reichert, Ashley Navarro, and Damon Hostin, Dignity Health Sacramento CME committee members, and all other planners involved and able to influence the content of this presentation have reported no relevant financial relationships/interest with any commercial entities that may have ties to this presentation.

 


Conference Chairperson: 

Costanzo DiPerna, MD

Vice President, Oncology Service Line, Dignity Health Cancer Institute of Greater Sacramento

Medical Director, Chest Disease Dignity Health, Dignity Health Mercy San Juan

Chief of Thoracic Surgery, Mercy Medical Group/Dignity Health Medical Foundation

 

Faculty:

Raja Flores, MD

Professor and Chairman, Department of Thoracic Surgery

Mount Sinai Health System

Brian Y. Merritt, MD, FCAP

Assistant Professor for Pathology & Immunology and Molecular & Human Genetics

Medical Director, Cancer Genetics Section

Baylor College of Medicine

Amardeep Singh, MD, FACC

Cardiologist

Mercy Medical Group

Ashley Navaro, MS, CGC

Genetic Counselor

Dignity Health Cancer Institute

Sonia Reichert, MD

Hematology & Oncology

Woodland Memorial Hospital

Damon Hostin

Chief Executive Officer, Precision Medicine Alliance

Catholic Health Initiatives and Dignity Health


Accreditation Statement:
Dignity Health Sacramento is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.

Credit Designation:
Dignity Health Sacramento designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes the use of American Joint Committee on Cancer (AJCC) or other appropriate staging in clinical practice, which includes the use of appropriate prognostic indicators and evidence-based national guidelines used in treatment planning.  

This activity is sponsored in part by promotional exhibitors

CME IMQ Logo